Home › Bladder Cancer › NCT04410302
Patient-Derived Xenografts to Reduce Cancer Health Disparities
University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities
Who can join
Ages 21 to 100 · All sexes
Full eligibility criteria
Inclusion Criteria: * Patient receiving treatment for the above 4 cancers (bladder cancer, lung cancer, gastric/stomach cancer, and liver cancer) * Signed informed consent that will be put on file Exclusion Criteria: * No informed consent obtained * Specimen unacceptable/degraded/etc. * Individuals who are not yet adults (infants, children, teenagers) * Pregnant women * Prisoners * Adults unable to consent
About the study
This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.
What is being tested
- Biospecimen Collection (procedure)
Sponsor: University of California, Davis · Participants: 500 · Started: Nov 12, 2019
Contact the study team
- Asst. Clinical Research Coordinator · Phone: 916-734-1587
Official record on ClinicalTrials.gov — NCT04410302
Locations in the U.S.
| California | UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange University of California Davis Comprehensive Cancer Center, Sacramento |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.